|  |  | 

India Top Headlines

Covaxin neutralizes UK strain: Biotech | India News

img-responsive

HYDERABAD / PUNE: India’s first indigenous Covid-19 vaccine, Covaxin, effectively neutralizes the most infectious UK variants of the SARS-CoV-2 virus, reducing the chance that the mutant virus will escape from the body’s defense system. This was stated by Covaxin developer, Bharat Biotech, on Wednesday after research conducted by the company together with experts from the National Institute of Virology (NIV) and the Indian Council for Medical Research (ICMR).
The study, which has not yet been peer-reviewed, concluded that the vaccine generated sufficient antibody capacity in recipients (who received two doses) to neutralize the mutated variant, also known as the B117 or 20B / 501Y.V1 lineage. The joint research paper, ‘Neutralization of UK variant VUI-202012/01 with Covaxin-vaccinated human serum’, has also been uploaded to bioRxiv, a server that carries preprints of the research paper before it is peer-reviewed. .
The paper said the researchers performed the plaque reduction neutralization test, which is used to quantify the titer or concentration of the neutralizing antibody to a virus, using sera collected from 26 volunteers who received Covaxin to test against the Kingdom variant. Kingdom and the heterologous strain of the virus. The researchers said that the neutralizing activity of the sera in both the UK variant and the heterologous strain showed similar efficiency.
The research team was led by ICMR CEO Balram Bhargava and Raches Ella, project leader: SARSCoV-2 vaccine and head of business development and promotion, Bharat Biotech. India has so far detected more than 100 cases of Covid-19 with the British variant of the virus.

Times of India

covaxin-neutralizes-uk-strain-biotech-india-news

ABOUT THE AUTHOR